Top news of the day from across the health care landscape.
Patients with psoriasis who do not receive proper disease education may not adhere to treatment, which can lead to worse outcomes, The American Journal of Managed Care reported. According to the article, a recent study examined the effect of an educational program on knowledge and self-expertise about psoriasis for patients with the disease. Patients were asked to fill out 2 questionnaires about disease knowledge, therapy adherence, and therapy satisfaction before and after the educational program. Overall, the educated patients showed a significant increase in knowledge, self-expertise about their disease, and general health after the program, the article reported.
Officials with the FDA declined to approve Adamis Pharmaceuticals’ opioid overdose treatment Zimhi, the company announced in a press release. According to Adamis, Zimhi, which is a naloxone pre-filled single-dose syringe, is designed to deliver high doses of naloxone for the emergency treatment of known or suspected opioid overdose. In a Complete Response Letter sent to the manufacturer, the FDA questioned the treatment’s manufacturing process, but not its safety or effectiveness, the release said.
A recent study suggests that antibiotic exposure may be linked to the risk of developing Parkinson disease, MD Magazine reported. According to the article, the study included 13,976 patients, as well as 40,697 control patients. Overall, the authors found that exposure to antianaerobics and tetracyclines 10 to 15 years before the index data, as well as suflonamides and trimethoprim 1 to 5 years before the index date and antifungal medication 1 to 5 years before the index date were positively associated with Parkinson disease risk, the article reported.